Shimadzu Showcases Automation at PharmSci 360
The company demonstrated new analytical instrumentation and sample preparation workflows at the New Orleans conference.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Do you trust that new analytical technology innovations effectively improve the safety of drug development?
Shimadzu presented its latest analytical technologies and automated pipelines at the AAPS 2026 PharmSci 360 conference in New Orleans. The exhibit highlighted advancements in bioanalytics and manufacturing automation.
Why it matters
The exhibits provided a platform to align high-precision analytical tools with emerging automation trends in the pharmaceutical sciences. By integrating these systems, the company addresses the industry demand for more efficient research workflows.
The showcase featured the GCMS-TQ RX Series, oligonucleotide characterization software, and the Nexera Prep LC. Shimadzu also demonstrated automated end-to-end sample preparation pipelines in partnership with ePrep.
The players
Shimadzu
A global manufacturer of precision analytical instrumentation, measuring instruments, and medical systems.
ePrep
A technology firm specializing in automated sample preparation solutions for laboratories.
The details
At Booth 1204, the company conducted active demonstrations of its analytical systems to support the conference tracks covering bioanalytics and automation. The collaboration with ePrep centered on developing streamlined pipelines designed for complex pharmaceutical samples.
Timeline
October 25-28, 2026: The AAPS 2026 PharmSci 360 conference occurred in New Orleans.
The Tech Race
This integration of automated pipelines represents a shift away from legacy manual processing toward interconnected laboratory ecosystems. It positions the company within a growing field of competitors striving to standardize and accelerate pharmaceutical development through digital automation.
These automated workflows aim to streamline complex lab tasks, potentially reducing the time required for sample analysis in pharmaceutical research. For researchers, this means a shift toward higher throughput and greater consistency in analytical outcomes.
The takeaway
The move toward end-to-end automation in laboratory settings is reducing the bottleneck effect often seen in traditional analytical pipelines. Practitioners can look to adopt similar integrated systems to improve overall lab productivity and data precision.
Further reading
Learn more about industry developments at the New Orleans Biotech section.
Source note: This article includes information reported by Selectscience.
Live Poll
Do you trust that new analytical technology innovations effectively improve the safety of drug development?
